EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study)

Fabio Catalano iD, Matteo Brunelli, Alessio Signori iD, Pasquale Rescigno iD, Sebastiano Buti iD, Luca Galli, Massimiliano Spada, Cristina Masini, Francesca Galuppini, Valerio Gaetano Vellone, Gabriele Gaggero, Marco Maruzzo iD und 15 weitere

Future Oncology · 2024

DOI: 10.2217/fon-2023-1068 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Future Oncology, 2024. Verfasst von Fabio Catalano und 26 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, 16132, Genoa, Italy. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Tumor Microenvironment, Kidney Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: LILT-Lega Italiana per la Lotta ai Tumori, LILT–Lega Italiana per la Lotta ai Tumori.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction: The Meet-URO 18 study is a multicentric study of patients with metastatic renal cell carcinoma receiving nivolumab in the second-line and beyond, categorized as responders (progression-free survival ≥ 12 months) and non-responders (progression-free survival < 3 months).Areas covered: The current study includes extensive immunohistochemical analysis of T-lineage markers (CD3, CD4, CD8, CD8/CD4 ratio), macrophages (CD68), ph-mTOR, CD15 and CD56 expression on tumor cells, and PD-L1 expression, on an increased sample size including 161 tumor samples (113 patients) compared with preliminary presented data. Responders' tumor tissue (n = 90; 55.9%) was associated with lower CD4 expression (p = 0.014), higher CD56 expression (p = 0.046) and higher CD8/CD4 ratio (p = 0.030).Expert opinion/commentary: The present work suggests the regulatory role of a subpopulation of T cells on antitumor response and identifies CD56 as a putative biomarker of immunotherapy efficacy. [Box: see text].

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellTumor MicroenvironmentKidney NeoplasmsHumansMaleFemaleNivolumabImmunotherapyAgedMiddle AgedProgression-Free SurvivalBiomarkers, TumorAdultImmune Checkpoint InhibitorsLymphocytes, Tumor-InfiltratingAntineoplastic Agents, Immunological

Stichwörter der Autor:innen

CD4CD56CD8PD-L1immune checkpoint inhibitorimmunotherapyrenal cell carcinomatumor microenvironment

Substanzen

NivolumabBiomarkers, TumorImmune Checkpoint InhibitorsAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, 16132, Genoa, Italy.
  • Pathology Unit, Department of Diagnostics & Public Health, University & Hospital Trust of Verona, 37124, Verona, Italy.
  • Department of Health Sciences (DISSAL), Section of Biostatistics, University of Genoa, 16132, Genoa, Italy.
  • Candiolo Cancer Institute, FPO-IRCCS, 10060, Candiolo, Italy.
  • Translational & Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle upon Tyne, NE1 7RU, UK.
  • Department of Medicine and Surgery, University of Parma, 43126, Parma, Italy.

ORCID-Profile: Fabio Catalano, Alessio Signori, Pasquale Rescigno, Sebastiano Buti, Marco Maruzzo, Michele Maffezzoli, Giuseppe Luigi Banna, Giuseppe Fornarini, Sara Elena Rebuzzi

Förderung

  • LILT-Lega Italiana per la Lotta ai Tumori
  • LILT–Lega Italiana per la Lotta ai Tumori

Zitieren

APA

Catalano, F., Brunelli, M., Signori, A., Rescigno, P., Buti, S., Galli, L., Spada, M., Masini, C., Galuppini, F., Vellone, V. G., Gaggero, G., Maruzzo, M., Merler, S., Vignani, F., Cavo, A., Bimbatti, D., Milella, M., Dei Tos, A. P., Sbaraglia, M., …, & Rebuzzi, S. E. (2024). Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study). Future Oncology. https://doi.org/10.2217/fon-2023-1068

Vancouver

Catalano F, Brunelli M, Signori A, Rescigno P, Buti S, Galli L, et al. Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study). Future Oncology. 2024. doi:10.2217/fon-2023-1068

BibTeX
@article{Catalano2024,
  author = {Catalano, Fabio and Brunelli, Matteo and Signori, Alessio and Rescigno, Pasquale and Buti, Sebastiano and Galli, Luca and Spada, Massimiliano and Masini, Cristina and Galuppini, Francesca and Vellone, Valerio Gaetano and Gaggero, Gabriele and Maruzzo, Marco and Merler, Sara and Vignani, Francesca and Cavo, Alessia and Bimbatti, Davide and Milella, Michele and Dei Tos, Angelo Paolo and Sbaraglia, Marta and Murianni, Veronica and Damassi, Alessandra and Cremante, Malvina and Maffezzoli, Michele and Llaja Obispo, Miguel Angel and Banna, Giuseppe Luigi and Fornarini, Giuseppe and Rebuzzi, Sara Elena},
  title = {Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study)},
  journal = {Future Oncology},
  year = {2024},
  doi = {10.2217/fon-2023-1068}
}
Kostenlos starten →